On October 21, 2021, ReCode Therapeutics, a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, announced the closing of an $80 million Series B financing round co-led by Pfizer Ventures and EcoR1 Capital. New investors include Sanofi Ventures, funds managed by Tekla Capital Management LLC, Superstring Capital, and NS Investment. Existing investors who participated included OrbiMed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures, L.P., and Osage University Partners (OUP). The proceeds from the Series B financing will be used to drive ReCode’s lead programs in primary ciliary dyskinesia (PCD) and cystic fibrosis (CF) into human clinical studies, expand the pipeline of treatments for patients with life-limiting genetic respiratory diseases, advance its LNP platform for organ-specific delivery of RNA and gene correction therapies, and increase internal manufacturing capabilities.

Wilson Sonsini Goodrich & Rosati represented ReCode Therapeutics in the transaction. The team includes:

Corporate
Ken Clark
Michael Coke
Christina Poulsen
Bartek Sudol
Eric Abram
Jennifer Gu

Technology Transactions – Biotech
Lowell Segal

Patent
Vern Norviel
Ali Alemozafar
Uale Taotafa

For more information, please see ReCode’s press release.